IRSA Inversiones y Representaciones S.A. reported a net loss of ARS 6,380 million for Q1 FY2027, a sharp decline from a profit of ARS 217,952 million in the same period last year, mainly due to losses from changes in the fair value of investment properties. Despite this, total Adjusted EBITDA increased by 9.3%, driven by stronger sales and development results, while rental segment EBITDA slightly declined by 2%. The company is expanding its shopping mall portfolio and maintains a high office occupancy rate of 96.9%. A dividend of ARS 211,000 million was approved, yielding 10.8%, with payments starting November 3, 2026.
IRSA Inversiones y Representaciones S.A announced its Q1 FY2027 results. For readers following the Real Estate sector, here is Pluang's market snapshot as of Nov 04, 2026 19:31 WIB: Out of 47 priced Real Estate-sector US stocks tradable on Pluang, 38 rose and 5 fell today. Notable price changes include Opendoor Technologies Inc at USD 1.78 (+2.30%), Omega Healthcare Investors Inc. at USD 48.49 (+2.02%), and Weyerhaeuser Company at USD 21.00 (+1.99%).
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
